Q-omics provides the consensus-scored TSPAN6 profile across patient tissues and cancer cell-line models. TSPAN6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, TSPAN6 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, TSPAN6 protein abundance shows 20,655 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight OV, KICH, and CCRCC as cancer lineages where TSPAN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN6 survival associations across molecular data types. TSPAN6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN6 RNA expression–survival associations across cancer types. High TSPAN6 expression shows unfavorable associations in KIRP, LGG and SARC, but favorable associations in OV, UVM and KIRC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for TSPAN6 RNA expression.
This table summarizes TSPAN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN6 shows lower tumor expression in KICH, KIRC, BRCA and HNSC and higher tumor expression in LUAD and LIHC. The KICH box plot shows higher TSPAN6 RNA expression in normal versus tumor tissue (log2 FC = −2.360, t-test p < 0.001).
This table shows molecular features associated with TSPAN6 in patient tissues and cancer cell lines. In patient samples, TSPAN6 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
